Mitochondrial-Based Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By designation

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Mitochondrial Inheritance

4.2.1 Symptoms

4.2.2 Diagnosis of mitochondrial disorders

4.3 Key Drivers

4.3.1 Technological Advancements

4.3.2 Increasing Number of Collaborations and Acquisitions

4.4 Key Barriers

4.4.1 Side-Effects Related with Various Drugs

4.5 Mitochondrial-Based Therapeutics Pipeline Analysis

4.5.1 Pipeline Analysis by Phase

4.5.2 Pipeline Analysis by Molecule Type

4.5.3 Pipeline Analysis by Route of Administration

Chapter 5. Mitochondrial-Based Therapeutics Pipeline Analysis by Phase (2019)

5.1 Phase III

5.1.1 Elamipretide

5.1.1.1 Pre-clinical studies

5.1.1.2 Clinical trials

5.1.1.3 Clinical trial results

5.1.1.4 Strategic developments

5.1.1.5 Designations

5.2 Phase II

5.2.1 MT1621

5.2.1.1 Clinical trials

5.2.1.2 Clinical trial results

5.2.1.3 Strategic developments

5.2.1.4 Designations

5.2.2 XXXX

5.2.2.1 Pre-clinical studies

5.2.2.2 Clinical trials

5.2.2.3 Clinical trial results

5.2.3 XXXX

5.2.3.1 Clinical trials

5.2.3.2 Clinical trial results

5.2.3.3 Strategic developments

5.2.3.4 Designations

5.2.3.5 Technology

5.2.3.6 Patent

5.2.4 XXXX

5.2.4.1 Clinical trials

5.2.4.2 Clinical trial results

5.2.4.3 Strategic developments

5.2.5 XXXX

5.2.5.1 Clinical trials

5.2.5.2 Clinical trial results

5.2.5.3 Strategic development

5.2.5.4 Designations

5.2.6 XXXX

5.2.6.1 Pre-clinical studies

5.2.6.2 Clinical trials

5.2.6.3 Strategic developments

5.3 Phase I

5.3.1 CB4211

5.3.1.1 Pre-clinical studies

5.3.1.2 Clinical trials

5.3.1.3 Strategic developments

5.3.1.4 Technology

5.3.2 XXXX

5.3.2.1 Clinical trial

5.3.3 XXXX

5.3.4 XXXX

5.3.4.1 Pre-clinical studies

5.3.4.2 Clinical trials

5.3.5 XXXX

5.3.5.1 Pre-clinical studies

5.3.5.2 Clinical trials

5.3.5.3 Clinical trial result

5.3.5.4 Strategic developments

5.3.5.5 Designations

5.3.6 XXXX

5.3.6.1 Pre-clinical results

5.3.6.2 Strategic developments

5.3.6.3 Designation

5.3.6.4 Patent

5.3.7 XXXX

5.3.7.1 Pre-clinical studies

5.3.7.2 Clinical trials

5.3.7.3 Strategic development

5.4 Pre-clinical

5.4.1 MP201

5.4.1.1 Pre-clinical results

5.4.1.2 Strategic developments

5.4.1.3 Patent

5.4.2 XXXX

5.4.2.1 Technology

5.4.3 XXXX

5.4.3.1 Pre-clinical studies

5.4.4 XXXX

5.4.4.1 Financing

5.4.4.2 Technology

5.4.5 XXXX

5.4.6 XXXX

5.4.6.1 Pre-clinical studies

5.4.6.2 Grants

5.4.7 XXXX

5.4.7.1 Pre-clinical studies

5.4.7.2 Strategic development

5.4.7.3 Designation

5.4.8 XXXX

5.4.9 XXXX

5.4.10 XXXX

5.4.10.1 Pre-clinical studies

5.4.10.2 Financing

5.5 Discovery

5.5.1 MDP Analogs – Cancer, Neurodegenerative Diseases, and Cardiovascular Diseases

5.5.2 XXXX

5.5.2.1 Strategic development

5.5.3 XXXX

5.5.3.1 Strategic developments

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Geography

6.2 Clinical Trials by Trial Status

Chapter 7. Regulatory Framework for Drug Approval

7.1 U.S.

7.2 Europe

7.2.1 Centralized Procedure

7.2.2 Mutual Recognition Procedure

7.2.3 Decentralized Procedure

7.2.4 Nationalized Procedure

7.3 Japan

Chapter 8. Competitive Landscape

8.1 Pipeline Players and Their Drug Offerings

8.2 SWOT Analysis

8.2.1 Strengths

8.2.2 Weaknesses

8.2.3 Opportunities

8.2.4 Threats

Chapter 9. Company Profiles

9.1 Khondrion BV

9.1.1 Business Overview

9.1.2 Product and Service Offerings

9.2 CohBar Inc.

9.2.1 Business Overview

9.2.2 Product and Service Offerings

9.3 XXXX

9.3.1 Business Overview

9.3.2 Product and Service Offerings

9.4 XXX.

9.4.1 Business Overview

9.4.2 Product and Service Offerings

9.5 XXXX

9.5.1 Business Overview

9.5.2 Product and Service Offerings

9.6 Stealth BioTherapeutics Inc.

9.6.1 Business Overview

9.6.2 Product and Service Offerings

9.7 XXXX

9.7.1 Business Overview

9.7.2 Product and Service Offerings

9.8 XXXX

9.8.1 Business Overview

9.8.2 Product and Service Offerings

9.9 XXXX.

9.9.1 Business Overview

9.9.2 Product and Service Offerings

9.10 XXXX

9.10.1 Business Overview

9.10.2 Product and Service Offerings

Chapter 10. Appendix

10.1 Abbreviations

10.2 Sources and References

10.3 Related Reports

List of Tables

TABLE 1 DESCRIPTION OF ELAMIPRETIDE

TABLE 2 CLINICAL TRIALS OF ELAMIPRETIDE

TABLE 3 DESIGNATIONS OF ELAMIPRETIDE

TABLE 4 DESCRIPTION OF MT1621

TABLE 5 CLINICAL TRIALS OF MT1621

TABLE 6 DESCRIPTION OF XXXX

TABLE 7 CLINICAL TRIALS OF XXXX

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 CLINICAL TRIALS OF XXXX

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 XXXX CLINICAL TRIALS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS AND CONDITIONS WITH SECONDARY MITOCHONDRIAL INVOLVEMENT

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF CB4211

TABLE 18 CLINICAL TRIALS OF CB4211

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 CLINICAL TRIAL OF XXXX

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 DESCRIPTION OF XXXX

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 CLINICAL TRIALS OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 DESCRIPTION OF XXXX

TABLE 27 CLINICAL TRIALS OF XXXX

TABLE 28 DESCRIPTION OF MP201

TABLE 29 DESCRIPTION OF XXXX

TABLE 30 DESCRIPTION OF XXXX

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 DESCRIPTION OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 DESCRIPTION OSF XXXX

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 KHONDRION BV – AT A GLANCE

TABLE 39 COHBAR INC. – AT A GLANCE

TABLE 40 XXXX – AT A GLANCE

TABLE 41 XXXX – AT A GLANCE

TABLE 42 XXXX – AT A GLANCE

TABLE 43 STEALTH BIOTHERAPEUTICS INC. – AT A GLANCE

TABLE 44 XXXX– AT A GLANCE

TABLE 45 XXXX – AT A GLANCE

TABLE 46 XXXX – AT A GLANCE

TABLE 47 XXXX – AT A GLANCE

TABLE 48 SOURCES AND REFERENCESS

List of Figures

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 4 MITOCHONDRIAL-BASED THERAPEUTICS UNDER DEVELOPMENT (2019)

FIG 5 MITOCHONDRIAL-BASED THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2019)

FIG 6 MITOCHONDRIAL-BASED THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2019)

FIG 7 BREAKDOWN OF CLINICAL TRIALS, BY GEOGRAPHY

FIG 8 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)

FIG 10 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)

FIG 11 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU

FIG 12 MARKETING AUTHORIZATION PROCEDURES IN EU

FIG 13 CENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 14 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL

FIG 15 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 16 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN

FIG 17 NUMBER OF DRUGS OFFERED BY PIPELINE PLAYERS, BY PHASE

FIG 18 SWOT ANALYSIS